How Payers Can Leverage the Cash Pharmacy and Discount Card Trend
Consumers have more choices for purchasing prescriptions without insurance. How can plans capture what they’re missing?
- Select Category
- Chronic Conditions
- Engagement
- Events
- Healthcare Costs
- Media
- Medication Adherence
- Member Stories
- Our Team
- Privacy and Security
- Product
- Success Stories
- Thought Leadership
- Transparency
- Uncategorized
- Select Category
- Chronic Conditions
- Engagement
- Events
- Healthcare Costs
- Media
- Medication Adherence
- Member Stories
- Our Team
- Privacy and Security
- Product
- Success Stories
- Thought Leadership
- Transparency
- Uncategorized
More Patients Turning to Cash Pharmacies and Discount Cards
Patients and plans both benefit from better medication access, affordability and adherence. Cash pharmacies and discount cards—in tandem with the pharmacy benefit—can help improve all three.
Prescription Delivery and Digital Pharmacies Consumer Adoption
The pandemic brought an uptick in prescription deliveries, yet they still lag behind most other online purchases. Here’s why that is bound to change.
7 Easy-to-Influence Survey Responses for Better Medicare Advantage Star Ratings
It’s too late to do anything about 2023 Medicare Star ratings. But it’s never too soon to influence what the next 1,000 random members surveyed will say about your plan.
The Great 2023 Humira Biosimilars Watch Is On – Here’s Where to Focus
Up to 10 competing products for Humira are on the way in 2023. What should health plans and plan sponsors be following as the biosimilars landscape takes shape?
Diabetes by the Numbers, and the Importance of Affordable Medication
Some lesser-known facts about this chronic condition underscore the importance of medication adherence, and the positive impact RxSS can have on members with diabetes.
A Q&A on the IRA
The Inflation Reduction Act has the potential to lower prescription drug costs for millions of Americans and raise them for millions more. Who stands to gain or lose?
The Adderall Shortage Is Real – Here’s How RxSS Helps Members
We know many members are scrambling to find pharmacies with the common ADHD medication in stock. With this and other drug shortages, RxSS can be an invaluable resource.
Humira and the Looming Biosimilar Boom
A wave of FDA-approved biosimilars for Humira and other costly biologics will enter the U.S. market in 2023. What does it mean for patients, payers and plan designs?
No, We’re Not Your Doctor—Just Transparency You Can Trust
Members shouldn’t confuse our clinical suggestions for intervention. Medication decisions are between patient and doctor. RxSS informs those discussions, and makes it easy to make a change.
Stay COnnected
Share your email and once a month we’llsend you industry news and insights.
